Vasopressin showed no clear difference in total mortalitya compared with norepinephrine (moderate certainty).
Vasopressin showed no clear difference in blood loss (ml) Estimated blood loss during myomectomy compared with placebo to reduce blood loss during myomectomy (moderate certainty).
Vasopressin probably leads to lower need for blood transfusion Participants who received blood transfusion compared with placebo to reduce blood loss during myomectomy (moderate certainty).
Vasopressin showed no clear difference in duration of surgery Operative time compared with placebo to reduce blood loss during myomectomy (moderate certainty).
It is very uncertain whether vasopressin receptor antagonists changes death compared with placebo or no treatment (very low certainty).
Vasopressin receptor antagonists probably leads to higher serum sodium concentration (response) compared with placebo or no treatment (moderate certainty).
Vasopressin receptor antagonists probably leads to higher rapid sodium increase compared with placebo or no treatment (moderate certainty).
Interventions to reduce blood loss during myomectomy for fibroids showed no clear difference in loop ligation of myoma pseudocapsule plus vasopressin compared with placebo or no treatment (low certainty).
Interventions to reduce blood loss during myomectomy for fibroids showed no clear difference in vasopressin compared with placebo or no treatment (moderate certainty).
Standard‐dose adrenaline (SDA) may leads to higher survival to hospital admission compared with vasopressin (low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes favourable neurological outcomes compared with vasopressin (very low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes return of spontaneous circulation compared with vasopressin (very low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes survival to hospital discharge compared with SDA plus vasopressin (very low certainty).
Standard‐dose adrenaline (SDA) showed no clear difference in survival to hospital admission compared with SDA plus vasopressin (low certainty).
It is very uncertain whether standard‐dose adrenaline (SDA) changes favourable neurological outcomes compared with SDA plus vasopressin (very low certainty).
Standard‐dose adrenaline (SDA) showed no clear difference in return of spontaneous circulation compared with SDA plus vasopressin (low certainty).